Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00361075 · ClinicalTrials.gov registry record · Phase 4
Midlife Cholesterol Study
A Phase 4 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT00361075 is a Phase 4 study that has completed, run by Northwestern University. The registered enrollment target is 120 participants.
The verdict
NCT00361075, a Phase 4 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
The postmenopausal state is associated with an increase risk for heart disease. Much of this increase in risk may be due to the loss of estrogen (the main female hormone) and the effect of this loss on lipids (blood fats). This loss of estrogen is often treated by estrogen replacement therapy. Estrogen replacement therapy seems to have a beneficial effect on lipid levels. The purpose of this research study is to understand 1) how menopause affects lipids and 2) how hormone replacement therapy effects the lipid metabolism of postmenopausal women.
Interventions
- DRUG transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1998-07 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00361075
The ClinicalTrials.gov registry entry for NCT00361075 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium) is the first listed.
NCT00361075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00361075 about?
NCT00361075 is a clinical study titled "Midlife Cholesterol Study". The postmenopausal state is associated with an increase risk for heart disease. Much of this increase in risk may be due to the loss of estrogen (the main female hormone) and the effect of this loss on lipids (blood fats). This loss of estrogen is often treated by estrogen replacement therapy. Estro...
What is the current status of trial NCT00361075?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 1998-07. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00361075?
The interventions under investigation include: transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium) (DRUG).
Who is sponsoring clinical trial NCT00361075?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.